biotech · Attention Deficit Hyperactivity Disorder · Vascular Ehlers-Danlos Syndrome · AYTU
AYTU BIOPHARMA
AYTU BIOPHARMA, INC
Aytu BioPharma is a biotech organization headquartered in Denver, USA. It trades on NYSE under ticker AYTU. Primary therapeutic focus areas include Attention Deficit Hyperactivity Disorder, Vascular Ehlers-Danlos Syndrom
Denver, USA HQ
2015 Founded
105 Employees
Public company Type
AYTU · NYSE Ticker
Company details
- Status
- Public
- HQ
- Denver, USA
- Founded
- 2015
- Employees
- 105
- Programs
- 3
- Drugs
- 5
- Patents
- 4
Enzastaurin
Phase 3 · small molecule · Vascular Ehlers-Danlos Syndrome
Enzastaurin for Vascular Ehlers-Danlos Syndrome is a Phase 3 program (small_molecule) at AYTU BIOPHARMA, INC with 1 ClinicalTrials.gov record(s).
Internal code AR101-PREVEnt
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- AYTU BIOPHARMA, INC
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Vascular Ehlers-Danlos Syndrome
- Status
- on_hold
- Trials
- 1